Papain-like protease of SARS-CoV-2 inhibits RLR signaling in a deubiquitination-dependent and deubiquitination-independent manner

19Citations
Citations of this article
11Readers
Mendeley users who have this article in their library.

Abstract

The newly emerged severe acute respiratory syndrome (SARS) coronavirus-2 (SARS-CoV-2) can result in dysregulated interferon (IFN) responses that contribute to disease severity. The papain-like protease of SARS-CoV-2 (SCoV2-PLpro) has been previously reported to attenuate IFN responses, but the underlying mechanism is not fully understood. In this study, we found that SCoV2-PLpro potently suppressed IFN production and signaling induced by Sendai virus as well as RIG-I-like receptor (RLR) signaling pathway components, including RIG-I, MAVS, TBK1, TRAF3, TRAF6, and IRF3. SCoV2-PLpro exhibited different specificity and efficiency than SARS-CoV PLpro, with the former exerting a greater inhibitory effect on the RIG-I- and TRAF3-mediated IFN response but a weaker effect on the MAVS-mediated IFN response. Furthermore, we showed that SCoV2-PLpro significantly reduced K63-ubiquitination of RIG-I, MAVS, TBK1, TRAF3, TRAF6, and IRF3 and K48-ubiquitination of IκBα, which are known critical for the innate immune signal transduction. The deubiquitinating (DUB) activity of SCoV2-PLpro required a catalytic residue cysteine 111 (C111) but not the UBL domain. Notably, by utilizing the DUB-defective C111 mutant, we demonstrated that SCoV2-PLpro targeted RLR signaling pathway regulators via deubiquitination-dependent and -independent mechanisms, with the inhibitory activities of RIG-I and TBK1 correlating with DUB function, whereas the antagonism effects on MAVS, TRAF3, TRAF6, and IRF3 independent on DUB activity. Overall, our results reveal that SCoV2-PLpro evolves differential IFN antagonism activity from SCoV1-PLpro and it targets multiple key RLR signaling pathway components via various mechanisms, providing insights into SARS-CoV-2 pathogenesis and clues for developing antiviral therapies for COVID-19.

References Powered by Scopus

Characteristics of SARS-CoV-2 and COVID-19

3507Citations
N/AReaders
Get full text

Identification and characterization of MAVS, a mitochondrial antiviral signaling protein that activates NF-κB and IRF3

2812Citations
N/AReaders
Get full text

Coronavirus biology and replication: implications for SARS-CoV-2

2079Citations
N/AReaders
Get full text

Cited by Powered by Scopus

A comprehensive review on pharmacologic agents, immunotherapies and supportive therapeutics for COVID-19

31Citations
N/AReaders
Get full text

The S1′–S3′ Pocket of the SARS-CoV-2 Main Protease Is Critical for Substrate Selectivity and Can Be Targeted with Covalent Inhibitors

13Citations
N/AReaders
Get full text

Progress of cGAS-STING signaling in response to SARS-CoV-2 infection

11Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Ran, X. H., Zhu, J. W., Chen, Y. Y., Ni, R. Z., & Mu, D. (2022). Papain-like protease of SARS-CoV-2 inhibits RLR signaling in a deubiquitination-dependent and deubiquitination-independent manner. Frontiers in Immunology, 13. https://doi.org/10.3389/fimmu.2022.947272

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 3

60%

Researcher 2

40%

Readers' Discipline

Tooltip

Biochemistry, Genetics and Molecular Bi... 3

60%

Social Sciences 1

20%

Immunology and Microbiology 1

20%

Article Metrics

Tooltip
Social Media
Shares, Likes & Comments: 6

Save time finding and organizing research with Mendeley

Sign up for free